Abstract:

Recurrent or metastatic cervical cancer characterized by rapid progression and extremely poor prognosis is a principal cause of death in patients. Medicines are available to treat recurrent or metastatic cervical cancer still represents an urgent unmet clinical need，with few effective chemotherapy agents，immunotherapy and molecular targeted therapyavailable. Tisotumab vedotin is an antibody ⁃ drug conjugate comprising a fully human monoclonal antibody specific for tissue factor conjugated to monomethyl auristatin E that has been engineered to target tissue factor expressing tumours. Tisotumab vedotin has been granted accelerated approval in the USA for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This paper，based on relevant domestic and foreign researches，summarizes and reviews the structure and mechanism of action，relevant clinical trials，common side effects and precautions of Tisotumab vedotin， in order to improve the readers understanding of this drug and to provide reference for clinicians to make rational decisions in practice.

Key words:

antibody drug conjugate, Tisotumab vedotin, cervical cancer, recurrent, metastatic, treat